That is exactly right. This will add to their revenues and profits, as well as set them up for the distribution of new drugs throughout the US. Cutting the middle man out is good. But, let's be clear, there will be a third party helping warehouse and ship. So there is that cost. But in aggregate, Elite will make more money and this makes sense and is exactly what I was hoping to hear.
And do not forget that Nasrat provided a little foreshadowing on ex-US sales...twice. So, just like his foreshadowing the Kirkov position, he just told us (in business speak) some firm ex-US and not Dexcel is "trying out" Elite's products. What are the odds that Kirkov had the relationship? Better than a coin flip!
Finally, can we all agree that Nasrat has explained ad nauseam that the pandemic has created issues with drug trials? In fact, if paying attention, this has been a problem for even the big pharma firms. So just stop with the nonsense about not doing what was promised. If Elite is able to put its big boy/girl pants on, then it is expected investors do the same.
News 
Market Data 
Discover 
AI
